Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys.

Gould RW, Gage HD, Banks ML, Blaylock BL, Czoty PW, Nader MA.

Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51. doi: 10.1016/j.neuropharm.2011.04.007. Epub 2011 Apr 17.

2.

Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys.

Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, Nader MA.

Neuropsychopharmacology. 2008 Jan;33(2):219-25. Epub 2007 Apr 18.

3.

In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.

Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramsøy T, Jernigan TL, Knudsen GM.

Arch Gen Psychiatry. 2011 Jun;68(6):562-76. doi: 10.1001/archgenpsychiatry.2011.56.

4.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

5.

Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27.

6.

MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding.

Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC.

Eur J Neurosci. 2007 Dec;26(11):3229-36. Epub 2007 Nov 14.

PMID:
18005064
7.

Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I.

Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17.

8.

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M.

Neuropsychopharmacology. 2012 May;37(6):1465-73. doi: 10.1038/npp.2011.332. Epub 2012 Feb 22.

9.

A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.

Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M.

Am J Psychiatry. 2004 Jul;161(7):1181-9.

PMID:
15229049
10.

Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys.

Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G.

Neuropsychopharmacology. 2004 Jul;29(7):1270-81.

11.

Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA.

J Nucl Med. 2002 May;43(5):678-92. Erratum in: J Nucl Med 2002 Jun;43(6):744.

12.
13.

Mapping of serotonin transporters by positron emission tomography with [11C]DASB in conscious common marmosets: comparison with rhesus monkeys.

Yokoyama C, Yamanaka H, Onoe K, Kawasaki A, Nagata H, Shirakami K, Doi H, Onoe H.

Synapse. 2010 Aug;64(8):594-601. doi: 10.1002/syn.20766.

PMID:
20340166
14.
15.

In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users.

Frokjaer VG, Erritzoe D, Holst KK, Madsen KS, Fisher PM, Madsen J, Svarer C, Knudsen GM.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1119-28. doi: 10.1017/S1461145714000066. Epub 2014 Feb 14.

PMID:
24524290
16.

Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings.

Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J.

Arch Gen Psychiatry. 2001 Oct;58(10):901-6.

PMID:
11576026
17.

3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice.

Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, Maldonado R.

Biol Psychiatry. 2007 Sep 15;62(6):669-79. Epub 2007 Feb 16.

PMID:
17306775
18.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
19.
20.

Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET.

Li IH, Huang WS, Shiue CY, Huang YY, Liu RS, Chyueh SC, Hu SH, Liao MH, Shen LH, Liu JC, Ma KH.

Neuroimage. 2010 Jan 15;49(2):1259-70. doi: 10.1016/j.neuroimage.2009.07.072. Epub 2009 Aug 12.

PMID:
19682588

Supplemental Content

Support Center